7,266 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Sabal Trust CO

Sabal Trust CO bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 7,266 shares of the life sciences company’s stock, valued at approximately $971,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in shares of Illumina in the 4th quarter valued at $32,000. TD Private Client Wealth LLC grew its holdings in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the period. V Square Quantitative Management LLC raised its holdings in Illumina by 50.6% in the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock valued at $52,000 after buying an additional 132 shares during the period. Finally, First Horizon Advisors Inc. boosted its stake in Illumina by 73.5% during the fourth quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock worth $59,000 after buying an additional 186 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 1.9 %

Shares of NASDAQ:ILMN opened at $95.73 on Wednesday. The company’s fifty day moving average is $126.02 and its two-hundred day moving average is $133.80. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 1-year low of $91.92 and a 1-year high of $156.66. The stock has a market capitalization of $15.16 billion, a price-to-earnings ratio of -12.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ILMN. Robert W. Baird lifted their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Royal Bank of Canada reduced their price objective on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Canaccord Genuity Group lowered their target price on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and reduced their price target for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Piper Sandler boosted their price objective on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.